RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban

Key Points:

• The FDA has scheduled advisory meetings in July 2024 and February 2027 to discuss lifting restrictions on 12 unproven peptides previously deemed unsafe in 2023, despite no new significant safety or efficacy data being available.
• The push to ease restrictions is largely driven by Health Secretary Robert F. Kennedy Jr., a vocal advocate for these peptides, who has promoted their use despite lacking scientific or medical credentials.
• Critics express concern that Kennedy may influence the advisory committee by appointing allies to secure favorable decisions without rigorous scientific review, similar to tactics used in vaccine advisory panels.
• The peptides under review, often marketed online for unproven health benefits such as injury repair and anti-aging, were removed from compounding pharmacy lists due to significant safety risks identified by the FDA.
• Experts emphasize that these peptides lack credible evidence of safety and effectiveness, urging that they undergo the standard FDA drug approval process instead of being reintroduced through a more lenient compounding pathway.